Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-alpha 2A and ribavirin therapy in patients with chronic hepatitis C

Imagem de Miniatura
Arquivos
art_TATENO_Dual_role_of_IL_12_in_the_therapeutic_2013.PDF (1.19 MB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2013
Editora
ELSEVIER SCIENCE BV
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
ARAUJO, Ana Ruth
PERUHYPE-MAGALHAES, Vanessa
COELHO-DOS-REIS, Jordana Grazziela Alves
CHAVES, Laura Patricia Viana
LIMA, Tatiane Amabili de
PIMENTEL, Joao Paulo Diniz
PAULA, Lucia de
ALMEIDA, Carlos Mauricio de
TARRAGO, Andrea Monteiro
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
IMMUNOLOGY LETTERS, v.154, n.1-2, p.61-69, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Several efforts have been made to establish novel biomarkers with relevant predictive values to monitor HCV-infected patients under pegilated Interferon-alpha 2A-(PEG-IFN-alpha 2A)/ribavirin therapy. The aim of this study was to monitor the kinetics of HCV viral load, serum levels of pro-inflammatory/regulatory cytokines and leukocyte activation status before and after PEG-IFN-alpha 2A/ribavirin therapy in 52 volunteers, including 12 chronic HCV patients and 40 controls. The HCV viral load, serum levels of cytokines (IL-8/IL-6/TNF-alpha/IL-12/IFN-gamma/IL-4/IL-10) and the phenotype of peripheral blood leukocytes were evaluated before and after 4, 12 and 24 weeks following the PEG-IFN-alpha 2A/ribavirin therapy. Our results demonstrated that sustained virological response-(SVR) is associated with early decrease in the viral load after 4 weeks of treatment. The presence of a modulated pro-inflammatory profile at baseline favors SVR, whereas a strong inflammatory response at baseline predisposes to therapeutic failure. Furthermore, a time-dependent increase on serum IL-12 levels in patients under treatment is critical to support the SVR, while the early predominance of IL-10 correlates to late virological relapse. On the other hand, a broad but unguided ""cytokine storm"" is observed in the non-responder HCV patients after 12 weeks of treatment. Corroborating these findings, monocyte/lymphocyte activation at baseline is associated with the non-responders to therapy whereas high CDS+ T-cell numbers associate with SVR. All in all, these data suggest that the baseline pattern of serum pro-inflammatory/regulatory cytokines and the immunological activation status of chronic HCV patients undergoing PEG-IFN-alpha 2A/ribavirin therapy are closely related with the therapeutic response.
Palavras-chave
HCV, PEG-IFN-alpha 2A/ribavirin, Viral load, Cytokines
URI
https://observatorio.fm.usp.br/handle/OPI/4498
Referências
  1. Aziz H, 2011, INFECT GENET EVOL, V11, P640, DOI 10.1016/j.meegid.2011.01.022
  2. Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
  3. Bucci C, 2013, J GEN VIROL
  4. Cramp ME, 2000, GASTROENTEROLOGY, V118, P346, DOI 10.1016/S0016-5085(00)70217-4
  5. Dai CY, 2009, HEPATOLOGY, V49, P2125, DOI 10.1002/hep.22826
  6. Freeman AJ, 2001, HEPATOLOGY, V34, P809, DOI 10.1053/jhep.2001.27831
  7. Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047
  8. Fujita N, 2011, MOL MED, V17, P70, DOI 10.2119/molmed.2010.00124
  9. Gelderblom HC, 2007, LIVER INT, V27, P944, DOI 10.1111/j.1478-3231.2007.01507.x
  10. Golden-Mason L, 2007, J VIROL, V81, P9249, DOI 10.1128/JVI.00409-07
  11. Grandi T, 2013, MEM I OSWALDO CRUZ, V108, P48, DOI 10.1590/S0074-02762013000100008
  12. Guobuzaite A, 2008, MED LITH, V44, P510
  13. Hanafiah KM, 2013, HEPATOLOGY, V57, P1333, DOI 10.1002/hep.26141
  14. Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227
  15. Kamal SM, 2004, HEPATOLOGY, V39, P1721, DOI 10.1002/hep.20266
  16. Kamal SM, 2002, GASTROENTEROLOGY, V123, P1070, DOI 10.1053/gast.2002.36045
  17. Kurosaki M, 2011, J GASTROENTEROL, V46, P401, DOI 10.1007/s00535-010-0322-5
  18. Ma CJ, 2011, IMMUNOLOGY, V132, P421, DOI 10.1111/j.1365-2567.2010.03382.x
  19. Maia LPV, 2009, J MED VIROL, V81, P1220, DOI 10.1002/jmv.21521
  20. Mangia A, 2013, J HEPATOL
  21. Martin-Carbonero L, 2008, AIDS, V22, P15
  22. Namikawa M, 2012, J GASTROEN HEPATOL, V27, P69, DOI 10.1111/j.1440-1746.2011.06802.x
  23. Nelson DR, 1998, HEPATOLOGY, V28, P225, DOI 10.1002/hep.510280129
  24. Sharafi H, 2012, HEPAT MON, V12, P190, DOI 10.5812/hepatmon.849
  25. Sharafi H, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.8387
  26. Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
  27. Shirakawa H, 2008, HEPATOLOGY, V48, P1753, DOI 10.1002/hep.22543
  28. SMITH DB, 1995, J GEN VIROL, V76, P1749, DOI 10.1099/0022-1317-76-7-1749
  29. Umemura T, 2011, ANTIVIR THER, V16, P1073, DOI 10.3851/IMP1869
  30. Waggoner SN, 2007, J LEUKOCYTE BIOL, V82, P1407, DOI 10.1189/jlb.0507268
  31. Wendel Silvano, 2007, Revista do Instituto de Medicina Tropical de Sao Paulo, V49, P177, DOI 10.1590/S0036-46652007000300008
  32. Yoneda S, 2011, J INFECT DIS, V203, P1087, DOI 10.1093/infdis/jiq165
  33. Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019664

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03